Search

Your search keyword '"Calvo‐Río, Vanesa"' showing total 177 results

Search Constraints

Start Over You searched for: Author "Calvo‐Río, Vanesa" Remove constraint Author: "Calvo‐Río, Vanesa"
177 results on '"Calvo‐Río, Vanesa"'

Search Results

4. ANCA detection with solid phase chemiluminescence assay: diagnostic and severity association in vasculitis

5. Mucosal Immune Defence Gene Polymorphisms as Relevant Players in the Pathogenesis of IgA Vasculitis?

7. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients

8. Uveitis in psoriatic arthritis: study of 406 patients in a single university center and literature review

9. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

10. Long-term follow-up of certolizumab pegol in uveitis due to immunemediated inflammatory diseases: multicentre study of 80 patients.

11. Baricitinib in severe and refractory peripheral ulcerative keratitis: a case report and literature review.

12. Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients

13. Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes

15. Brief Report: Association of HLA–DRB1*01 With IgA Vasculitis (Henoch-Schönlein)

16. Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases

17. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients

18. Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy

19. Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients

20. Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study

21. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients

22. Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. National multicenter study of 51 cases in clinical practice.

23. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

24. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice

25. SAT0219 EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS INDEPENDENTLY OF THE INICIAL PREDNISONE DOSE

26. FRI0269 COMPARATIVE STUDY OF INFLIXIMAB VERSUS ADALIMUMAB IN REFRACTORY UVEITIS DUE TO BEHÇET’S DISEASE. NATIONAL MULTICENTER STUDY OF 177 CASES

27. AB0762 TREATMENT WITH TOFACITINIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF CLINICAL PRACTICE

28. THU0566 OCULAR FEATURES IN 381 PATIENTS WITH SYSTEMIC SARCOIDOSIS AND ITS CORRELATION WITH THE IWOS CRITERIA. STUDY IN A UNIVERSITY HOSPITAL

29. SAT0235 BIOLOGICAL THERAPYIN NEUROBEHÇET. MULTICENTER STUDY OF 29 PATIENTS

30. FRI0277 ISCHEMIC AND SYSTEMIC SYMPTOMS IN GIANT CELL ARTERITIS PATIENTS, RESPONSE TO TOCILIZUMAB

31. FRI0276 TIME OF DISEASE EVOLUTION AND EFFICACY OF TOCILIZUMAB IN GIANT CELL ARTERITIS

32. FRI0202 SHORT AND LONG-TERM FOLLOW-UP OF APREMILAST THERAPY IN REFRACTORY SKIN LUPUS LESIONS

33. AB1077 ANTI-IL6-RECEPTOR TOCILIZUMAB IN GRAVES’ ORBITOPATHY. MULTICENTER STUDY OF 46 PATIENTS IN CLINICAL PRACTICE

34. THU0292 EXTRACRANIAL VESSEL INVOLVEMENT IN PATIENTS WITH GIANT CELL ARTERITIS

35. FRI0604 SYSTEMIC SARCOIDOSIS. STUDY OF 381 PATIENTS FROM A TERTIARY UNIVERSITY HOSPITAL IN THE NORTH OF SPAIN

36. THU0581 BIOLOGICAL THERAPY IN NON ISCHAEMIC OPTIC NEURITIS ASSOCIATED TO IMMUNE-MEDIATED INFLAMMATORY DISEASES. MULTICENTER STUDY

37. SAT0220 USE OF TOCILIZUMAB IN AORTITIS. A MULTICENTER STUDY OF 79 PATIENTS

38. OP0339 TOCILIZUMAB IN GIANT CELL ARTERITIS. MONOTHERAPY VERSUS COMBINED WITH CONVENTIONAL IMMUNOSUPPRESSIVE DRUGS

39. SAT0215 APREMILAST IN REFRACTORY ORAL AND/OR GENITAL ULCERS IN BEHÇET’S DISEASE. MULTICENTER STUDY OF 49 CASES IN CLINICAL PRACTICE

40. FRI0038 HERPES ZOSTER IN RHEUMATOID ARTHRITIS. PROSPECTIVE SINGLE CENTER STUDY OF 390 RA PATIENTS FOR 5YEARS

41. AB0577 TOCILIZUMAB IN GIANT CELL ARTERITIS. ROUTE OF ADMINISTRACION: INTRAVENOUS OR SUBCUTANEOUS

42. FRI0270 APREMILAST IN NON-ULCER MANIFESTATIONS IN BEHçET’S DISEASE. MULTICENTER STUDY OF 32 CASES IN CLINICAL PRACTICE

43. THU0288 LONG-TERM FOLLOW-UP OF ANTI-IL6-RECEPTOR TOCILIZUMAB IN REFRACTORY UVEITIS IN PATIENTS WITH BEHÇET’S DISEASE. MULTICENTER STUDY OF 14 PATIENTS IN CLINICAL PRACTICE

44. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients

45. Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica

46. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet’s disease associated uveitis: a systematic review

47. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease

48. The Spectrum of Paraneoplastic Cutaneous Vasculitis in a Defined Population

49. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study

50. Relapses in patients with Henoch–Schönlein purpura

Catalog

Books, media, physical & digital resources